部分中文Onoact处方资料（仅供参考）
抗心律失常药兰地洛尔。2002年7月，日本小野药品工业公司开发的手术时心动过速性心律失常(心房纤维性颤动、心房扑动及窦性心动过速)治疗药兰地洛尔(Onoact，landiolol)获得厚生省批准。手术时，由于气管内插管及拔管、切开皮肤以及手术操作等对身体的各种刺激，引起交感神经兴奋，释放出过剩的儿茶酚胺，使心搏数增加，易引发心动过速性心律失常。特别是伴有缺血性心脏疾病及高血压的患者，仅仅由于心搏数增加就会增强心脏的负荷，从而引起冠状动脉等缺血。兰地洛尔即是针对于此而开发的药品。
作为一种选择性β1受体阻断药，兰地洛尔主要拮抗存在于心脏的β1受体，通过抑制由儿茶酚胺引起的心搏数增加，改善心动过速性心律失常。它在血中半衰期极短，约为4分钟。与现有的β受体阻断药不同，兰地洛尔专用于手术时心动过速性心律失常的紧急处置。
手术时，由于气管内插管及拔管、切开皮肤以及手术操作等对身体的各种刺激，引起交感神经兴奋，释放出过剩的儿茶酚胺，使心博数增加，易引发心动过速性心律失常。特别是伴有缺血性心脏疾病及高血压的患者，仅仅由于心博数增加就会增强心脏的负荷，从而引起冠状动脉等缺血。
Onoact即是针对于此而开发的药品。本品为选择性β1受体阻断药，主要拮抗存在于心脏的β1受体，通过抑制由儿茶酚胺引起的心博数增加，改善心动过速性心律失常。本品血中半衰期极短，约为4分钟。与现有的β受体阻断药不同，本品专用于手术时心动过速性心律失常的紧急处置。
本品1安瓿中含有盐酸兰地洛尔50mg。通常，以每分钟0.125mg/kg的速度静脉内给药1分钟，然后调节速度在每分钟0.01～0.04mg/Kg静脉内持续给药。
一般名
ランジオロール塩酸塩（Landiolol Hydrochloride）
化学名
(-)-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl 3-{4-[(S)-2-hydroxy-3-(2-morpholinocarbonyl-amino)ethylamino]propoxy}phenylpropionate monohydrochloride
構造式
分子式
C25H39N3O8・HCl
分子量
546.05
性状
白色の結晶性の粉末で、水、メタノールに極めて溶けやすく、エタノール（99.5）にやや溶けやすい。
融点
約125℃
分配係数
0.23（pH6.0、n-オクタノール／緩衝液）
0.56（pH7.0、n-オクタノール／緩衝液）
2.7（pH8.0、n-オクタノール／緩衝液）
包装
注射用オノアクト50（50mg）：5バイアル、10バイアル
製造販売
小野薬品工業株式会社
完整说明附件：http://www.info.pmda.go.jp/go/pack/2123404D1025_1_10/
 |
Announcement of the Launch of Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Kimiichiro Matsumoto) will launch Onoact® 50 for injection, the drug for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia), on September 6, 2002.
During operation, various invasive procedures on a living body, such as endotracheal intubation, extubation, skin incision and other surgical procedures, facilitate the excessive discharge of catecholamine (noradrenaline, adrenalin, etc.) mainly from the sympathetic nerve, leading to an increase in heart rate, as well as tachyarrhythmia.
Especially in patients with ischemic heart disease and/or hypertension, even a slightly increased heart rate may constitute an additional burden on the heart, and induce ischemia at coronary artery etc. Therefore, the development of a drug that can be easily titrated for emergency treatment of intraoperative tachyarrhythmia has long been awaited.
Onoact® 50 for injection, which has been developed to fulfill these medical needs, improves tachyarrhythmia by selectively blocking β1 receptors located chiefly in the heart, and by inhibiting the action of catecholamine that raises the heart rate.
Onoact® 50 for injection can be used in emergency treatment of intraoperative tachyarrhythmia, because this fast-acting drug can be easily titrated for its very short half-life in blood (approx. 4 min). We expect that Onoact® 50 for injection will be widely used as an innovative frontline drug.
Product Profile of Onoact® for Injection
Nonproprietary name : Landiolol hydrochloride
Active ingredient : 50 mg landiolol hydrochloride per vial
Indications : Emergency treatment for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia)
Dosage and administration : Landiolol hydrochloride is intravenously administered at 0.125 mg/kg/min for one minute, and at 0.04 mg/kg/min thereafter. The dosage should be appropriately adjusted between 0.01 and 0.04 mg/kg/min, based on the heart rate and blood pressure to be measured during the infusion.
Package : 5 vials or 10 vials of Onoact® for injection
Manufactured and distributed by : Ono Pharmaceutical Co., Ltd.
---------------------------------------------------------------
原产地英文商品名:
Onoact(オノアクト)50mg/vial 5vials/box
原产地英文药品名:
Landiolol
中文参考商品译名:
Onoact(オノアクト)50毫克/瓶 5瓶/盒
中文参考药品译名:
兰地洛尔
生产厂家中文参考译名:
小野药品工业公司
生产厂家英文名:
Ono Pharmaceutical Co., Ltd.
